Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study

Hirotsugu Kenmotsu, Kazuko Sakai, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Ryo Koyama, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Yuki Sato, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kazuto Nishio, Toshiaki Takahashi

Open source

DOI: 10.1016/j.jtocrr.2024.100716
Published: 2024-11
Container: JTO Clinical and Research Reports
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2024.100716,
  title = {Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study},
  author = {Hirotsugu Kenmotsu and Kazuko Sakai and Keita Mori and Terufumi Kato and Shunichi Sugawara and Keisuke Kirita and Yasuto Yoneshima and Koichi Azuma and Kazumi Nishino and Shunsuke Teraoka and Ryo Koyama and Ken Masuda and Hidetoshi Hayashi and Ryo Toyozawa and Satoru Miura and Yuki Sato and Kazuhiko Nakagawa and Nobuyuki Yamamoto and Kazuto Nishio and Toshiaki Takahashi},
  year = {2024},
  journal = {JTO Clinical and Research Reports},
  doi = {10.1016/j.jtocrr.2024.100716},
  url = {https://doi.org/10.1016/j.jtocrr.2024.100716}
}

RIS

TY  - JOUR
TI  - Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
AU  - Hirotsugu Kenmotsu
AU  - Kazuko Sakai
AU  - Keita Mori
AU  - Terufumi Kato
AU  - Shunichi Sugawara
AU  - Keisuke Kirita
AU  - Yasuto Yoneshima
AU  - Koichi Azuma
AU  - Kazumi Nishino
AU  - Shunsuke Teraoka
AU  - Ryo Koyama
AU  - Ken Masuda
AU  - Hidetoshi Hayashi
AU  - Ryo Toyozawa
AU  - Satoru Miura
AU  - Yuki Sato
AU  - Kazuhiko Nakagawa
AU  - Nobuyuki Yamamoto
AU  - Kazuto Nishio
AU  - Toshiaki Takahashi
PY  - 2024
JO  - JTO Clinical and Research Reports
DO  - 10.1016/j.jtocrr.2024.100716
UR  - https://doi.org/10.1016/j.jtocrr.2024.100716
ER  -

APA

Kenmotsu, H., Sakai, K., Mori, K., Kato, T., Sugawara, S., Kirita, K., Yoneshima, Y., Azuma, K., Nishino, K., Teraoka, S., Koyama, R., Masuda, K., Hayashi, H., Toyozawa, R., Miura, S., Sato, Y., Nakagawa, K., Yamamoto, N., Nishio, K., & Takahashi, T. (2024). Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study. JTO Clinical and Research Reports. https://doi.org/10.1016/j.jtocrr.2024.100716

Source records

crossref · retrieved 2026-09-25T15:36:32.460Z